Ken Griffin Baxter International Inc Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$32.85 - $40.26 $6.01 Million - $7.36 Million	182,900 Added 50.54%	544,800 $20.7 Million
Q2 2024 Aug 14, 2024	SELL	$32.87 - $43.55 $3.2 Million - $4.24 Million	-97,400 Reduced 21.21%	361,900 $12.1 Million
Q1 2024 May 15, 2024	SELL	$37.88 - $43.77 $11.3 Million - $13 Million	-298,000 Reduced 39.35%	459,300 $19.6 Million
Q4 2023 Feb 14, 2024	BUY	$31.71 - $38.95 $6.04 Million - $7.42 Million	190,400 Added 33.59%	757,300 $29.3 Million
Q3 2023 Nov 14, 2023	SELL	$37.32 - $49.29 $4.6 Million - $6.07 Million	-123,200 Reduced 17.85%	566,900 $21.4 Million
Q2 2023 Aug 14, 2023	BUY	$39.98 - $47.68 $3.99 Million - $4.75 Million	99,700 Added 16.89%	690,100 $31.4 Million
Q1 2023 May 15, 2023	BUY	$37.58 - $52.57 $4.24 Million - $5.93 Million	112,800 Added 23.62%	590,400 $23.9 Million
Q4 2022 Feb 14, 2023	BUY	$49.7 - $57.71 $10.5 Million - $12.2 Million	211,200 Added 79.28%	477,600 $24.3 Million
Q3 2022 Nov 14, 2022	SELL	$53.86 - $66.8 $533,214 - $661,320	-9,900 Reduced 3.58%	266,400 $14.3 Million

1,008

451M

2.79M

2.44M

Ticker BAX
Exchange NYSE
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 504,120,992
Market Cap $16.8B
Description
Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; intravenous therapies, infusion pumps, administration sets, and drug reconstitution devices; remixed and oncology drug pl...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.